Dr. Venkat emphasizes individualized care for upper tract urothelial carcinoma cases
“We’re not doing enough lymph node dissections in upper tract disease,” says Siv Venkat, MD, FRCSC.
In this video, Siv Venkat, MD, FRCSC, discusses the takeaways and further research associated with the study, “Comparison of radical nephroureterectomy and segmental ureterectomy in upper tract urothelial carcinoma,” presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Venkat is a urologic oncology fellow at Weill Cornell Medicine and New York-Presbyterian Hospital in New York City, New York.
Cell therapy TARA-002 shows initial promise in NMIBC
April 9th 2024"This encouraging anti-tumor activity coupled with a favorable safety profile and mode of administration that is both convenient and familiar to urologists indicates that, if confirmed in future studies, TARA-002 could potentially play a meaningful role in NMIBC treatment in the future," says Timothy D. Lyon, MD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Nadofaragene firadenovec shows durable efficacy in NMIBC
April 8th 2024"In this follow-up analysis of the phase 3 study, we demonstrated a sustained response to Adstiladrin treatment over 3 years, allowing more than half of the patients in the study to remain cystectomy free for at least 36 months,” says Colin P.N. Dinney, MD.
